India's noodle row and spill-over effects for pharma
This article was originally published in Scrip
Executive Summary
Nestle's run-in with Indian regulators over its popular noodle brand, Maggi, being "unsafe" and hazardous" for human consumption may just have put the spotlight on the fast-growing nutraceuticals segment quite like the heightened focus on site compliance in the aftermath of "Ranbaxygate" some years ago.
You may also be interested in...
Star Power: How Celebrity Endorsement Is Shaping Pharma In India
Pharma in India draws on celebrity endorsement to spotlight specific disease conditions, with social media adding new dimensions to these efforts. But do these campaigns, now facing increasing disclosure scrutiny more widely, deliver a return on investment?
Star Power: How Celebrity Endorsement Is Shaping In India Pharma
Pharma in India draws on celebrity endorsement to spotlight specific disease conditions, with social media adding new dimensions to these efforts. But do these campaigns, now facing increasing disclosure scrutiny more widely, deliver a return on investment?
US NCI’s Gravitt On Stepping Up Cancer Control Efforts In Asia-Pacific
Dr Patti Gravitt, Deputy Director, Center for Global Health, US National Cancer Institute, in an interview with Scrip, discusses a range of strategies underway and proposed to strengthen cancer control efforts in the Asia Pacific. HPV vaccination and a regional cancer control dashboard are among the areas she highlighted.